Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalSTU:SD4 +1.23%14 Net Margin % is -329.54% as of Mar. 2026. GuruFocus rates STU:SD4 with a GF Score™ of 14/100 and a GF Value™ of €0.56 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 93.6% on this metric.
The historical rank and industry rank for Spectral Medical's Net Margin % or its related term are showing as below:
STU:SD4'
s Net Margin % Range Over the Past 10 Years
Min: -1952.99 Med: -436.58 Max: -64.82
Current: -1377.18
STU:SD4's Net Margin % is ranked worse than 93.6% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.81
vs STU:SD4: -1377.18
Spectral Medical (STU:SD4) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Spectral Medical Net Margin % Related Terms
Spectral Medical Net Margin % Historical Data
* Premium members only.
The historical data trend for Spectral Medical's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:SD4 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Spectral Medical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Net Margin % distribution charts can be found below:
* The bar in red indicates where Spectral Medical's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical (STU:SD4) has a Net Margin % of -329.54% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Spectral Medical and its competitors. According to the industry distribution chart, Spectral Medical ranks #190 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 93.6%.
Is Spectral Medical's Net Margin % too high?
Spectral Medical's current Net Margin % is -329.54%. Based on the distribution chart, Spectral Medical ranks #190 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Spectral Medical has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #190 out of 203 companies for Net Margin %. This places Spectral Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Spectral Medical and its competitors. Spectral Medical's current Net Margin % is -329.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (STU:SD4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.56, compared to a current price of €0.83 — trading 47.3% above its estimated fair value. The current Net Margin % is -329.54%. Spectral Medical's overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Spectral Medical (STU:SD4), the current Net Margin % is -329.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (STU:SD4) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of €0.83 is trading 47.3% above its estimated GF Value™ of €0.56.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for STU:SD4:
Net Margin %: -329.54%
GF Value™: €0.56 vs. price of €0.83 (47.3% above fair value)
No single metric tells the full story. See the STU:SD4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
14GF Score
Get the complete analysis for STU:SD4
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SD4 has been successfully added to your 
